REGENXBIO Inc.

For the period ended Nov 5, 2026. Filed Nov 5, 2026.

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Nov 5, 2026 · Filed Nov 5, 2026

Use the contents to explore the available documents and sections.

RGNX$7.62+3.3%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

EX-99.1 · (in thousands, except per share data)

(in thousands, except per share data)

Three Months · Nine Months
	Ended September 30,		Ended September 30,
	2026	2025	2026	2025
Revenues
License and royalty revenue	$5,244	$23,605	$114,175	$129,119
Service revenue	3,918	6,128	9,399	10,985
Total revenues	9,162	29,733	123,574	140,104
Operating Expenses (Income)
Cost of license and royalty revenues	1,141	5,725	13,257	14,370
Research and development	61,009	56,101	174,434	168,688
General and administrative	20,579	20,253	63,501	60,483
Gain on litigation settlement	(38,026)	—	(38,026)	—
Other operating expenses (income)	(7)	65	41	125
Total operating expenses	44,696	82,144	213,207	243,666
Loss from operations	(35,534)	(52,411)	(89,633)	(103,562)
Other Income (Expense)
Interest income from licensing	16	19	49	65
Investment income	2,252	3,620	5,477	9,500
Interest expense	(7,472)	(13,169)	(23,973)	(32,732)
Total other income (expense)	(5,204)	(9,530)	(18,447)	(23,167)
Net loss	$(40,738)	$(61,941)	$(108,080)	$(126,729)
Other Comprehensive Income (Loss)
Unrealized gain (loss) on available-for-sale securities, net	(170)	98	(358)	89
Total other comprehensive income (loss)	(170)	98	(358)	89
Comprehensive loss	$(40,908)	$(61,843)	$(108,438)	$(126,640)
Net loss per share, basic and diluted	$(0.62)	$(1.20)	$(1.90)	$(2.46)
Weighted-average common shares outstanding, basic and diluted	65,263	51,689	56,884	51,513

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.